clinical trial of Molnupiravir Capsules, to be used for the treatment of Covid-19 positive patients.The capsule has been developed by American pharma major Merck along with Ridgeback Biotherapeutics.According to a press release from Natco, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication."Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy," it said.Natco is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients."Compassionate use" approval is given for.